381 related articles for article (PubMed ID: 14981738)
1. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.
Lehky TJ; Leonard GD; Wilson RH; Grem JL; Floeter MK
Muscle Nerve; 2004 Mar; 29(3):387-92. PubMed ID: 14981738
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
[TBL] [Abstract][Full Text] [Related]
4. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
[TBL] [Abstract][Full Text] [Related]
5. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
Argyriou AA; Cavaletti G; Briani C; Velasco R; Bruna J; Campagnolo M; Alberti P; Bergamo F; Cortinovis D; Cazzaniga M; Santos C; Papadimitriou K; Kalofonos HP
Cancer; 2013 Jan; 119(2):438-44. PubMed ID: 22786764
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.
Sittl R; Carr RW; Fleckenstein J; Grafe P
Neurotoxicology; 2010 Dec; 31(6):694-700. PubMed ID: 20670646
[TBL] [Abstract][Full Text] [Related]
7. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
[TBL] [Abstract][Full Text] [Related]
8. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Exp Neurol; 2011 Jan; 227(1):120-7. PubMed ID: 20965170
[TBL] [Abstract][Full Text] [Related]
9. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients.
Taieb S; Trillet-Lenoir V; Rambaud L; Descos L; Freyer G
Cancer; 2002 May; 94(9):2434-40. PubMed ID: 12015768
[TBL] [Abstract][Full Text] [Related]
10. Acute oxaliplatin-induced peripheral nerve hyperexcitability.
Wilson RH; Lehky T; Thomas RR; Quinn MG; Floeter MK; Grem JL
J Clin Oncol; 2002 Apr; 20(7):1767-74. PubMed ID: 11919233
[TBL] [Abstract][Full Text] [Related]
11. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up.
Pietrangeli A; Leandri M; Terzoli E; Jandolo B; Garufi C
Eur Neurol; 2006; 56(1):13-6. PubMed ID: 16825773
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin-associated neuropathy: a review.
Cersosimo RJ
Ann Pharmacother; 2005 Jan; 39(1):128-35. PubMed ID: 15590869
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin and axonal Na+ channel function in vivo.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Clin Cancer Res; 2006 Aug; 12(15):4481-4. PubMed ID: 16899592
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
[TBL] [Abstract][Full Text] [Related]
16. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
Argyriou AA; Polychronopoulos P; Iconomou G; Koutras A; Makatsoris T; Gerolymos MK; Gourzis P; Assimakopoulos K; Kalofonos HP; Chroni E
Acta Oncol; 2007; 46(8):1131-7. PubMed ID: 17851880
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Oncology; 2009; 77(6):342-8. PubMed ID: 20016227
[TBL] [Abstract][Full Text] [Related]
18. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
Land SR; Kopec JA; Cecchini RS; Ganz PA; Wieand HS; Colangelo LH; Murphy K; Kuebler JP; Seay TE; Needles BM; Bearden JD; Colman LK; Lanier KS; Pajon ER; Cella D; Smith RE; O'Connell MJ; Costantino JP; Wolmark N
J Clin Oncol; 2007 Jun; 25(16):2205-11. PubMed ID: 17470850
[TBL] [Abstract][Full Text] [Related]
19. Pain in oxaliplatin-induced neuropathy--sensitisation in the peripheral and central nociceptive system.
Binder A; Stengel M; Maag R; Wasner G; Schoch R; Moosig F; Schommer B; Baron R
Eur J Cancer; 2007 Dec; 43(18):2658-63. PubMed ID: 17855072
[TBL] [Abstract][Full Text] [Related]
20. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
